Perioperative morbidity and mortality of high-dose-rate gynecologic brachytherapy

Daniel G. Petereit, Jann N Sarkaria, Rick J. Chappell

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Purpose: To determine the 30-day morbidity and mortality rates for patients with an intact uterus undergoing high-dose-rate (HDR) brachytherapy, and to assess risk factors which may predict for these potentially life- threatening complications. Methods and Materials: From August 1989 to December 1994, 128 cervical and 41 medically inoperable endometrial cancer patients were treated with 5 outpatient weekly HDR brachytherapy insertions. Patients with cervical cancer also were treated with external beam radiotherapy. Acute events that resulted in either hospitalization (morbidity) or death (mortality) within 30 days of the implant were analyzed. Univariate and multivariate analyses were performed to identify risk factors. Results: Overall there were 16 acute events in 169 patients (9.5%). The overall morbidity and mortality rates for the cervical and endometrial patients were 5.5 %, 1.6 %, 7.3 %, and 9.8 %, respectively. The following factors were significant by univariate analysis: age per decade, American Society of Anesthesiologists (ASA) score, Karnofsky Performance Status (KPS), significant medical history, diagnosis of cervical vs. endometrial cancer, and mean time exceeding 160 minutes for the procedure. Since age was the most significant predictive factor (p = 0.0003), bivariate analyses were performed by adjusting for age. In these analyses only ASA and KPS maintained significance, while a positive medical history was of borderline significance (p = 0.07). Conclusion: The morbidity and mortality rates observed in gynecologic patients selected for HDR brachytherapy were similar to low- dose-rate, but higher than other HDR reports. Reasons for this include a higher risk population, especially those with medically inoperable endometrial cancer. In the cervical cancer patients, some of the complications may have also been a result of the external beam portion of the radiation. In order to minimize the acute complications observed in the present HDR brachytherapy system, the following changes have been implemented: appropriate patient selection, anesthesiology involvement to monitor conscious sedation for high-risk patients, external beam radiotherapy alone in patients at extremely high risk, deep vein thrombosis (DVT) prophylaxis, use of intraoperative ultrasound, shorter duration in the brachytherapy suite, and preradiation treatment plans (plans executed prior to the insertion) if applicable. Finally, this analysis suggests that these procedures should be performed in a hospital-based setting where appropriate support is available.

Original languageEnglish (US)
Pages (from-to)1025-1031
Number of pages7
JournalInternational Journal of Radiation Oncology Biology Physics
Volume42
Issue number5
DOIs
StatePublished - Dec 1 1998
Externally publishedYes

Fingerprint

mortality
Brachytherapy
Morbidity
dosage
Mortality
cancer
Endometrial Neoplasms
Karnofsky Performance Status
Uterine Cervical Neoplasms
anesthesiology
Radiotherapy
insertion
radiation therapy
prophylaxis
Conscious Sedation
histories
thrombosis
uterus
Anesthesiology
Venous Thrombosis

Keywords

  • Cervical cancer
  • Complications
  • HDR brachytherapy
  • Inoperable endometrial cancer
  • Morbidity
  • Mortality

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiation

Cite this

Perioperative morbidity and mortality of high-dose-rate gynecologic brachytherapy. / Petereit, Daniel G.; Sarkaria, Jann N; Chappell, Rick J.

In: International Journal of Radiation Oncology Biology Physics, Vol. 42, No. 5, 01.12.1998, p. 1025-1031.

Research output: Contribution to journalArticle

@article{d94e02c887374f7fbb616d8b339deea5,
title = "Perioperative morbidity and mortality of high-dose-rate gynecologic brachytherapy",
abstract = "Purpose: To determine the 30-day morbidity and mortality rates for patients with an intact uterus undergoing high-dose-rate (HDR) brachytherapy, and to assess risk factors which may predict for these potentially life- threatening complications. Methods and Materials: From August 1989 to December 1994, 128 cervical and 41 medically inoperable endometrial cancer patients were treated with 5 outpatient weekly HDR brachytherapy insertions. Patients with cervical cancer also were treated with external beam radiotherapy. Acute events that resulted in either hospitalization (morbidity) or death (mortality) within 30 days of the implant were analyzed. Univariate and multivariate analyses were performed to identify risk factors. Results: Overall there were 16 acute events in 169 patients (9.5{\%}). The overall morbidity and mortality rates for the cervical and endometrial patients were 5.5 {\%}, 1.6 {\%}, 7.3 {\%}, and 9.8 {\%}, respectively. The following factors were significant by univariate analysis: age per decade, American Society of Anesthesiologists (ASA) score, Karnofsky Performance Status (KPS), significant medical history, diagnosis of cervical vs. endometrial cancer, and mean time exceeding 160 minutes for the procedure. Since age was the most significant predictive factor (p = 0.0003), bivariate analyses were performed by adjusting for age. In these analyses only ASA and KPS maintained significance, while a positive medical history was of borderline significance (p = 0.07). Conclusion: The morbidity and mortality rates observed in gynecologic patients selected for HDR brachytherapy were similar to low- dose-rate, but higher than other HDR reports. Reasons for this include a higher risk population, especially those with medically inoperable endometrial cancer. In the cervical cancer patients, some of the complications may have also been a result of the external beam portion of the radiation. In order to minimize the acute complications observed in the present HDR brachytherapy system, the following changes have been implemented: appropriate patient selection, anesthesiology involvement to monitor conscious sedation for high-risk patients, external beam radiotherapy alone in patients at extremely high risk, deep vein thrombosis (DVT) prophylaxis, use of intraoperative ultrasound, shorter duration in the brachytherapy suite, and preradiation treatment plans (plans executed prior to the insertion) if applicable. Finally, this analysis suggests that these procedures should be performed in a hospital-based setting where appropriate support is available.",
keywords = "Cervical cancer, Complications, HDR brachytherapy, Inoperable endometrial cancer, Morbidity, Mortality",
author = "Petereit, {Daniel G.} and Sarkaria, {Jann N} and Chappell, {Rick J.}",
year = "1998",
month = "12",
day = "1",
doi = "10.1016/S0360-3016(98)00349-6",
language = "English (US)",
volume = "42",
pages = "1025--1031",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Perioperative morbidity and mortality of high-dose-rate gynecologic brachytherapy

AU - Petereit, Daniel G.

AU - Sarkaria, Jann N

AU - Chappell, Rick J.

PY - 1998/12/1

Y1 - 1998/12/1

N2 - Purpose: To determine the 30-day morbidity and mortality rates for patients with an intact uterus undergoing high-dose-rate (HDR) brachytherapy, and to assess risk factors which may predict for these potentially life- threatening complications. Methods and Materials: From August 1989 to December 1994, 128 cervical and 41 medically inoperable endometrial cancer patients were treated with 5 outpatient weekly HDR brachytherapy insertions. Patients with cervical cancer also were treated with external beam radiotherapy. Acute events that resulted in either hospitalization (morbidity) or death (mortality) within 30 days of the implant were analyzed. Univariate and multivariate analyses were performed to identify risk factors. Results: Overall there were 16 acute events in 169 patients (9.5%). The overall morbidity and mortality rates for the cervical and endometrial patients were 5.5 %, 1.6 %, 7.3 %, and 9.8 %, respectively. The following factors were significant by univariate analysis: age per decade, American Society of Anesthesiologists (ASA) score, Karnofsky Performance Status (KPS), significant medical history, diagnosis of cervical vs. endometrial cancer, and mean time exceeding 160 minutes for the procedure. Since age was the most significant predictive factor (p = 0.0003), bivariate analyses were performed by adjusting for age. In these analyses only ASA and KPS maintained significance, while a positive medical history was of borderline significance (p = 0.07). Conclusion: The morbidity and mortality rates observed in gynecologic patients selected for HDR brachytherapy were similar to low- dose-rate, but higher than other HDR reports. Reasons for this include a higher risk population, especially those with medically inoperable endometrial cancer. In the cervical cancer patients, some of the complications may have also been a result of the external beam portion of the radiation. In order to minimize the acute complications observed in the present HDR brachytherapy system, the following changes have been implemented: appropriate patient selection, anesthesiology involvement to monitor conscious sedation for high-risk patients, external beam radiotherapy alone in patients at extremely high risk, deep vein thrombosis (DVT) prophylaxis, use of intraoperative ultrasound, shorter duration in the brachytherapy suite, and preradiation treatment plans (plans executed prior to the insertion) if applicable. Finally, this analysis suggests that these procedures should be performed in a hospital-based setting where appropriate support is available.

AB - Purpose: To determine the 30-day morbidity and mortality rates for patients with an intact uterus undergoing high-dose-rate (HDR) brachytherapy, and to assess risk factors which may predict for these potentially life- threatening complications. Methods and Materials: From August 1989 to December 1994, 128 cervical and 41 medically inoperable endometrial cancer patients were treated with 5 outpatient weekly HDR brachytherapy insertions. Patients with cervical cancer also were treated with external beam radiotherapy. Acute events that resulted in either hospitalization (morbidity) or death (mortality) within 30 days of the implant were analyzed. Univariate and multivariate analyses were performed to identify risk factors. Results: Overall there were 16 acute events in 169 patients (9.5%). The overall morbidity and mortality rates for the cervical and endometrial patients were 5.5 %, 1.6 %, 7.3 %, and 9.8 %, respectively. The following factors were significant by univariate analysis: age per decade, American Society of Anesthesiologists (ASA) score, Karnofsky Performance Status (KPS), significant medical history, diagnosis of cervical vs. endometrial cancer, and mean time exceeding 160 minutes for the procedure. Since age was the most significant predictive factor (p = 0.0003), bivariate analyses were performed by adjusting for age. In these analyses only ASA and KPS maintained significance, while a positive medical history was of borderline significance (p = 0.07). Conclusion: The morbidity and mortality rates observed in gynecologic patients selected for HDR brachytherapy were similar to low- dose-rate, but higher than other HDR reports. Reasons for this include a higher risk population, especially those with medically inoperable endometrial cancer. In the cervical cancer patients, some of the complications may have also been a result of the external beam portion of the radiation. In order to minimize the acute complications observed in the present HDR brachytherapy system, the following changes have been implemented: appropriate patient selection, anesthesiology involvement to monitor conscious sedation for high-risk patients, external beam radiotherapy alone in patients at extremely high risk, deep vein thrombosis (DVT) prophylaxis, use of intraoperative ultrasound, shorter duration in the brachytherapy suite, and preradiation treatment plans (plans executed prior to the insertion) if applicable. Finally, this analysis suggests that these procedures should be performed in a hospital-based setting where appropriate support is available.

KW - Cervical cancer

KW - Complications

KW - HDR brachytherapy

KW - Inoperable endometrial cancer

KW - Morbidity

KW - Mortality

UR - http://www.scopus.com/inward/record.url?scp=0032435418&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032435418&partnerID=8YFLogxK

U2 - 10.1016/S0360-3016(98)00349-6

DO - 10.1016/S0360-3016(98)00349-6

M3 - Article

VL - 42

SP - 1025

EP - 1031

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 5

ER -